FDA
-
-
-
-
-
-
-
Insmed reports successful phase 3b trial for lung disease drug ARIKAYCE
-
-
-
-
-
-
-
European regulators recommend Insmed's BRINSUPRI for rare lung disease
-
-
-
-
-
-
-
Insmed (INSM) PT Raised to $145 at Stifel
-
-
-
-
-
-
-
Insmed (INSM) Announces Pricing of $750 Million Public Offering of Common Stock
-
-
-
-
-
-
-
Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension
-
-
-
-
-
-
-
Insmed (INSM) Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis
-
-
-
-
-
-
-
Barclays shares outlook for Biotech in 2025, names preferred stocks
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

